Klinische Fortschritte in der Gastroenterologie

Einleitung

Die Gastroenterologie als ein Schwerpunkt der Inneren Medizin hat in den letzten Jahren eine rasante Entwicklung durchlaufen. Die Fortschritte in der Diagnostik und Therapie einer Vielzahl gastroenterologischer Krankheitsbilder beruhen zum einen auf dem besseren Verständnis der Ätiologie und Pathomechanismen, zum anderen auf Erkenntnissen aus evidenzbasierten experimentellen und klinischen Multicenterstudien. Im Folgenden sollen organbezogen (Ösophagus, Magen, Pankreas, Leber, Dünn- und Dickdarm) klinisch besonders relevante, aktuelle Entwicklungen beleuchtet werden. Dies kann hier nur in kursorischer, exemplarischer Form geschehen. Die Autoren erheben dabei keinen Anspruch auf Vollständigkeit.

Literatur

• 1 Koop H, Schepp W, Muller-Lissner S. et al . Consensus conference of the DGVS on gastroesophageal reflux.  Z Gastroenterol. 2005;  43 163-164
• 2 Schepp W, Allescher H D, Frieling T. et al . Topic complex I: Definitions, epidemiology and natural course.  Z Gastroenterol. 2005;  43 165-168
• 3 Koop H, Classen M, Liebe S, Lutke A, Wienbeck M. Therapy of non-erosive reflux disease (NERD).  Z Gastroenterol. 2005;  43 176-179
• 4 Laine L, Ahnen D, McClain C, Solcia E, Walsh J H. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.  Aliment Pharmacol Ther. 2000;  14 651-668
• 5 Messmann H, Ell C, Fein M. et al . Complex VI: Barrett esophagus.  Z Gastroenterol. 2005;  43 184-190
• 6 Behrens A, May A, Gossner L. et al . Curative treatment for high-grade intraepithelial neoplasia in Barrett’s esophagus.  Endoscopy. 2005;  37 999-1005
• 7 Li Y, Wo J M, Ray M B. et al . Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett’s esophagus to adenocarcinoma.  Gastroenterol. 2006;  12 928-934
• 8 Morgner-Miehlke A, Koop H, Blum A L. et al . Symptom- versus Endoscopy-Based Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD).  Z Gastroenterol. 2006;  44 399-410
• 9 Leontiadis G I, Sharma V K, Howden C W. Proton pump inhibitor treatment for acute peptic ulcer bleeding.  Cochrane Database Syst Rev. 2006;  1
• 10 Vergara M, Catalan M, Gisbert J P, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.  Aliment Pharmacol Ther. 2005;  21 1411-1418
• 11 Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology.  Eur J Surg Oncol. 2005;  31 453-460
• 12 Macdonald J S, Smalley S R, Benedetti J. et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.  N Engl J Med. 2001;  345 725-730
• 13 Kwon R S, Brugge W R. New advances in pancreatic imaging.  Curr Opin Gastroenterol. 2005;  21 561-567
• 14 Meier R, Ockenga J, Pertkiewicz M. et al . ESPEN Guidelines on Enteral Nutrition: Pancreas.  Clin Nutr. 2006;  Epub ahead of print
• 15 Moyshenyat I, Mandell E, Tenner S. Antibiotic prophylaxis of pancreatic infection in patients with necrotizing pancreatitis: rationale, evidence, and recommendations.  Curr Gastroenterol Rep. 2006;  8 121-126
• 16 Lankisch P G, Lerch M M. The role of antibiotic prophylaxis in the treatment of acute pancreatitis.  J Clin Gastroenterol. 2006;  40 149-155
• 17 Penner R, Fedorak R N, Madsen K L. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases.  Curr Opin Pharmacol. 2005;  5 596-603
• 18 Maisonneuve P, Lowenfels A B, Mullhaupt B. et al . Cigarette smoking accelerates progression of alcoholic chronic pancreatitis.  Gut. 2005;  54 510-514
• 19 Chari S T, Leibson C L, Rabe K G. et al . Probability of pancreatic cancer following diabetes: a population-based study.  Gastroenterology. 2005;  129 504-511
• 20 Moore M J. Brief communication: a new combination in the treatment of advanced pancreatic cancer.  Semin Oncol. 2005;  (6 Suppl 8) 32 5-6
• 21 Lau G K, Piratvisuth T, Luo K X. et al . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2005;  352 2682-2695
• 22 Chan H L, Hui A Y, Wong V W. et al . Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.  Hepatology. 2005;  41 1357-1364
• 23 Mangia A, Santoro R, Minerva N. et al . Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.  N Engl J Med. 2005;  352 2609-2617
• 24 Berg T, von Wagner M, Nasser S. et al . Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.  Gastroenterology. 2006;  130 1086-1097
• 25 Schilsky M L, Fink S. Inherited metabolic liver disease.  Curr Opin Gastroenterol. 2006;  22 215-222
• 26 Marrero J A. Hepatocellular carcinoma.  Curr Opin Gastroenterol. 2006;  22 248-253
• 27 Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.  Hepatology. 2006;  43 S99-S112
• 28 Eliakim A R. Video capsule endoscopy of the small bowel (PillCam SB).  Curr Opin Gastroenterol. 2006;  22 124-127
• 29 Golder S K, Schreyer A G, Endlicher E. et al . Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease.  Int J Colorectal Dis. 2006;  21 97-104
• 30 Yamamoto H, Kita H. Double-balloon endoscopy: from concept to reality.  Gastrointest Endosc Clin N Am. 2006;  16 347-361
• 31 Heine G D, Hadithi M, Groenen M J. et al . Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease.  Endoscopy. 2006;  38 42-48
• 32 Ell C, May A, Nachbar L. et al . Push-and-pull enteroscopy in the small bowel using the double-balloon technique: results of a prospective European multicenter study.  Endoscopy. 2005;  37 613-616
• 33 Spiller R, Campbell E. Post-infectious irritable bowel syndrome.  Curr Opin Gastroenterol. 2006;  22 13-21
• 34 Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine.  Curr Opin Gastroenterol. 2004;  20 82-88
• 35 Hanauer S B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.  Inflamm Bowel Dis. 2006;  12 S3-9
• 36 Kruis W, Fric P, Pokrotnieks J. et al . Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.  Gut. 2004;  53 1617-1616
• 37 Jarnerot G, Hertervig E, Friis-Liby I. et al . Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.  Gastroenterology. 2005;  128 1805-1811
• 38 Rutgeerts P, Sandborn W J, Feagan B G. et al . Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;  353 2462-2426
• 39 Mulhall B P, Veerappan G R, Jackson J L. Meta-analysis: computed tomographic colonography.  Ann Intern Med. 2005;  142 635-650
• 40 Hartmann D, Bassler B, Schilling D. et al . Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy.  Radiology. 2006;  238 143-149
• 41 Kiesslich R, Hoffman A, Neurath M F. Colonoscopy, tumors, and inflammatory bowel disease - new diagnostic methods.  Endoscopy. 2006;  38 5-10
• 42 Dekker E, Fockens P. Advances in colonic imaging: new endoscopic imaging methods.  Eur J Gastroenterol Hepatol. 2005;  17 803-808
• 43 Kiesslich R, Gotz M, Neurath M F, Galle P R. Endomicroscopy-technology with future.  Internist. 2006;  47 8-17
• 44 Vucelic B, Rex D, Pulanic R. et al . The aer-o-scope: proof of concept of a pneumatic, skill-independent, self-propelling, self-navigating colonoscope.  Gastroenterology. 2006;  130 672-677